Enel Health®Atlas
Sign in
Enel Health®Atlas
Browse libraries

Not medical advice. The Atlas is not a substitute for a clinician who can examine you.

Andarine (S-4)

GTx-007, Nonsteroidal SARM

Evidence grade 2 of 5, Thin. Read how the Atlas grades evidence.

The written rationale for this grade is still being prepared.

FDA
Not FDA approved; did not advance past early development
WADA
Prohibited at all times (S1.2 Other Anabolic Agents)

Reference only. Not medical advice.

What can go wrong

Dose-dependent visual disturbance (yellow tint, poor night vision); HPTA suppression with reduced testosterone/LH/FSH; lipid effects and SARM-class hepatic concerns. Products are unregulated and frequently mislabeled. Banned in WADA sport.

This is something to take to a clinician. The Atlas can tell you what is known about andarine (s-4) in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.

Andarine (S-4, GTx-007) is one of the earliest nonsteroidal SARMs, developed by GTx. It is best known for a distinctive dose-dependent visual side effect, a yellow tint to vision (xanthopsia) and impaired night/low-light adaptation, attributed to interaction with androgen receptors in the eye. Largely because of this, andarine did not advance far in development. It persists in the gray market despite the tolerability problem.

The SARM that tints your vision yellow, a side effect that helped kill its development.

What people take it for

These are the reasons people give for taking it. They are not effects it has been shown to have.

  • Marketed (illegally) for lean-mass, cutting and bone support

How it is supposed to work

Andarine is a nonsteroidal AR agonist favoring anabolic activity in muscle and bone. Its notorious visual effect is thought to arise from binding at androgen receptors in ocular tissue, producing reversible xanthopsia and reduced dark adaptation that worsen with dose.

A tolerability problem, not just a quirk

The yellow-vision effect is not a curiosity, it is a dose-limiting adverse effect that helped stall andarine's development in favor of cleaner SARMs like ostarine and ligandrol. Users routinely report the tint and difficulty seeing at night; it is generally reversible on discontinuation but is a clear signal of off-target activity.

Safety in detail

Andarine causes a distinctive, dose-dependent visual side effect and suppresses the HPT axis. It is an unapproved drug that never cleared early development, and self-administration carries documented tolerability and endocrine risks.

Replacement is not the same as a cycle

No validated human dose exists; the visual side effect intensifies with dose, so higher gray-market dosing worsens the most characteristic harm.

What it does to fertility

As an AR agonist it suppresses LH/FSH and endogenous testosterone, which can impair spermatogenesis; human data are limited.

What has to be monitored

The bloodwork this needs, and the reason it belongs with a clinician rather than a website.

  • Vision/ophthalmologic symptoms
  • Total/free testosterone, LH, FSH
  • Lipid panel
  • Liver function tests

What people get wrong

  • Often saidAndarine is a clean cutting SARM

    ActuallyIts signature effect is a dose-dependent yellow tint and night-vision impairment, an off-target adverse effect, not a clean profile.

  • Often saidThe vision effect is harmless

    ActuallyIt is reversible but reflects androgen-receptor activity in the eye and is a dose-limiting problem that hampered development.

Who profits, and who pushes back

Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.

How we got here

Andarine (S-4, GTx-007) was among the first-generation SARMs from GTx and the University of Tennessee group. Promising anabolic data in animals were offset by the visual side-effect signal, and GTx prioritized ostarine over S-4. Andarine never reached meaningful human efficacy trials but lingers in bodybuilding use.

  1. Early 2000sGTx develops S-4 (GTx-007)
  2. Mid-2000sAnabolic preclinical data published; visual side effect noted
  3. 2010sSuperseded by ostarine/ligandrol; persists in gray market

At a glance

Developer
GTx, Inc.
Code
GTx-007
Signature effect
Yellow-tinted / impaired night vision
FDA approvals
None

What this entry does not yet cover

What follows is unfinished work on our side, not a finding about Andarine (S-4). A short entry is not a safe entry.

  • Cost and market. We have not documented what it sells for or who sells it.
  • Supply chain. We have not mapped where it is made.
  • Who uses it. We have not documented the user groups.
  • What could change. No forward-looking summary yet.
  • How it compares. We have not set it against the alternatives.
  • Children and teenagers. We have not checked what is known about younger people.

Sources

The studies below are named and described, but not linked. You cannot open them from here and check our reading against them, which means this page is our summary of the literature rather than a document you can verify. Weigh it accordingly until the links exist.

The studies that matter

  • Preclinical characterization of S-4 (Gao/Dalton, GTx)2004-2005

    Anabolic activity in muscle and bone in castrated-rat models; tissue-selective profile